Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01366885 · ClinicalTrials.gov registry record · Phase 2

Vitamin D to Prevent Autism in Newborn Siblings

A Phase 2 study, sponsored by Oregon Health and Science University.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT01366885 is a Phase 2 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01366885, a Phase 2 study, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether by administering vitamin D to mothers who already have at least one child with autism and who are pregnant, that the vitamin D will prevent the recurrence of autism in the newborn sibling.

Interventions

  • DRUG Vitamin D3

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2008-02
Est. Completion 2016-02
Phase Phase 2

What the Registry Record Tells You About NCT01366885

The ClinicalTrials.gov registry entry for NCT01366885 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Vitamin D3 is the first listed.

NCT01366885 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01366885 about?

NCT01366885 is a clinical study titled "Vitamin D to Prevent Autism in Newborn Siblings". The purpose of this study is to determine whether by administering vitamin D to mothers who already have at least one child with autism and who are pregnant, that the vitamin D will prevent the recurrence of autism in the newborn sibling.

What is the current status of trial NCT01366885?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2008-02. Estimated completion is 2016-02.

What interventions are being tested in trial NCT01366885?

The interventions under investigation include: Vitamin D3 (DRUG).

Who is sponsoring clinical trial NCT01366885?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.